AstraZeneca PLC (AZN)
77.76
+0.15
(+0.19%)
USD |
NASDAQ |
May 10, 09:34
AstraZeneca Accounts Payable (Quarterly): 19.70B for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 19.70B |
December 31, 2023 | 3.267B |
September 30, 2023 | 20.54B |
June 30, 2023 | 19.74B |
March 31, 2023 | 19.21B |
December 31, 2022 | 2.55B |
September 30, 2022 | 17.69B |
June 30, 2022 | 17.82B |
March 31, 2022 | 17.86B |
December 31, 2021 | 2.824B |
September 30, 2021 | 18.66B |
June 30, 2021 | 17.73B |
March 31, 2021 | 17.37B |
December 31, 2020 | 2.35B |
September 30, 2020 | 13.41B |
June 30, 2020 | 12.03B |
March 31, 2020 | 12.63B |
December 31, 2019 | 1.774B |
September 30, 2019 | 12.54B |
June 30, 2019 | 12.64B |
March 31, 2019 | 13.10B |
December 31, 2018 | 1.72B |
September 30, 2018 | 10.99B |
June 30, 2018 | 10.91B |
March 31, 2018 | 11.48B |
Date | Value |
---|---|
December 31, 2017 | 2.285B |
September 30, 2017 | 10.83B |
June 30, 2017 | 10.07B |
March 31, 2017 | 9.899B |
December 31, 2016 | 1.68B |
September 30, 2016 | 9.961B |
June 30, 2016 | 10.26B |
March 31, 2016 | 11.17B |
December 31, 2015 | 3.469B |
September 30, 2015 | 10.59B |
June 30, 2015 | 10.66B |
March 31, 2015 | 10.51B |
December 31, 2014 | 3.492B |
September 30, 2014 | 10.15B |
June 30, 2014 | 10.30B |
March 31, 2014 | 10.63B |
December 31, 2013 | 2.499B |
September 30, 2013 | 9.242B |
June 30, 2013 | 9.642B |
March 31, 2013 | 9.465B |
December 31, 2012 | 2.449B |
September 30, 2012 | 8.629B |
June 30, 2012 | 8.972B |
March 31, 2012 | 8.945B |
December 31, 2011 | 8.975B |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
1.774B
Minimum
Dec 2019
20.54B
Maximum
Sep 2023
13.12B
Average
15.39B
Median
Accounts Payable (Quarterly) Benchmarks
GSK PLC | 18.46B |
Amgen Inc | 1.628B |
Sanofi SA | -- |
Viking Therapeutics Inc | 5.225M |
Fusion Pharmaceuticals Inc | 1.86M |